drugset / Trial / NCT02337062

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

NCT02337062

Phase 3 Completed 1147 enrolled Acacia Pharma Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).

Timeline

Start
2015-02
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule Intravenous

Indications

No indication recorded.